{"id":479077,"date":"2020-04-13T11:18:02","date_gmt":"2020-04-13T11:18:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=479077"},"modified":"2020-04-13T11:18:02","modified_gmt":"2020-04-13T11:18:02","slug":"actinic-keratosis-market-insights-epidemiology-and-market-forecast-2030","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/actinic-keratosis-market-insights-epidemiology-and-market-forecast-2030_479077.html","title":{"rendered":"Actinic Keratosis Market Insights, Epidemiology, and Market Forecast 2030"},"content":{"rendered":"
\"Actinic<\/a><\/div>\n

(Albany, US) DelveInsight has launched a new report on Actinic Keratosis Market Insights, Epidemiology and Market Forecast-2030<\/strong><\/p>\n

DelveInsight’s “Actinic Keratosis – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Actinic Keratosis , historical and forecasted epidemiology as well as the Actinic Keratosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n

The Actinic Keratosis market report provides current treatment practices, emerging drugs, Actinic Keratosis market share of the individual therapies, current and forecasted Actinic Keratosis market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Actinic Keratosis treatment practice\/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.<\/p>\n

Actinic keratosis (AK)<\/strong> is a chronic and prevalent disease affecting areas of sun-exposed skin where visible and subclinical, non-visible lesions coexist.This area of sun-damaged skin is prone to the development of further visible AK lesions and sun-related skin cancer and is known as ‘field cancerization’.  AK lesions are being represented as small scaly patches that can be flat or slightly raised. Their color can range from one’s skin tone to a reddish-brown color. They differ in size from 3mm to 10mm across, and they may gradually enlarge.AK lesions appear on areas which are most commonly exposed to sun, such as the face, scalp, shoulders, neck, the back of the hands and forearms, etc.<\/p>\n

\"\"<\/p>\n

 <\/p>\n

Request for :- free sample page<\/a><\/strong><\/p>\n

Epidemiology<\/strong><\/p>\n

The Actinic Keratosis epidemiology division provide insights about historical and current Actinic Keratosis patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.<\/p>\n

Reports key facts:- <\/strong><\/p>\n

1. As per the estimation by DelveInsight’s analysts, the United States had the highest prevalence of Actinic Keratosis with 66,733,101 prevalent population in 2017.<\/p>\n

2. Among the EU5 countries, Germany had the highest prevalent population with 8,294,972 <\/strong>cases followed by the United Kingdom with prevalent population of 5,419,455 <\/strong>in 2017. On the other hand, Japan has the lowest prevalent population with 700,954 <\/strong>cases in 2017.<\/p>\n

“According to the study conducted by Green et al., titled “Epidemiology of Actinic Keratoses”, AK prevalence is higher among men than women of the same age. In Northern European and North American whites, AKs are uncommon before the age of 40 years”<\/strong><\/em><\/p>\n

Key companies are working on this disease that are given below:-<\/strong><\/em><\/p>\n

1. Bausch Health Companies
2. Sandoz Phamaceuticals
3. LEO Pharma<\/p>\n

Name of drugs covered that are given below:- <\/strong><\/em><\/p>\n

1. Aldara
2. Zyclara
3. Solaraze<\/p>\n

Table of content<\/strong><\/em><\/a><\/p>\n

1. Key Insights<\/span><\/p>\n

2. Executive Summary of Actinic Keratosis<\/span><\/p>\n

3. Competitive Intelligence Analysis for Actinic Keratosis<\/span><\/p>\n

4. Actinic Keratosis : Market Overview at a Glance<\/span><\/p>\n

4.1. Actinic Keratosis Total Market Share (%) Distribution in 2017<\/span><\/p>\n

4.2. Actinic Keratosis Total Market Share (%) Distribution in 2030<\/span><\/p>\n

5. Actinic Keratosis : Disease Background and Overview<\/span><\/p>\n

6. Patient Journey<\/span><\/p>\n

7. Actinic Keratosis Epidemiology and Patient Population<\/span><\/p>\n

8. Treatment Algorithm, Current Treatment, and Medical Practices<\/p>\n

8.1. Actinic Keratosis Treatment and Management<\/span><\/p>\n

8.2. Actinic Keratosis Treatment Algorithm <\/span><\/p>\n

9. Unmet Needs<\/span><\/p>\n

10. Key Endpoints of Actinic Keratosis Treatment<\/span><\/p>\n

11. Marketed Products<\/span><\/p>\n

12. Emerging Therapies<\/p>\n

13. Actinic Keratosis : Seven Major Market Analysis<\/p>\n

14. Attribute analysis<\/p>\n

15. 7MM: Market Outlook<\/span><\/p>\n

16. Access and Reimbursement Overview of Actinic Keratosis<\/p>\n

17. KOL Views<\/span><\/p>\n

18. Market Drivers<\/span><\/p>\n

19. Market Barriers<\/span><\/p>\n

20. Appendix<\/span><\/p>\n

20.1. Bibliography<\/span><\/p>\n

20.2. Report Methodology<\/span><\/p>\n

21. DelveInsight Capabilities<\/span><\/p>\n

22. Disclaimer<\/span><\/p>\n

23. About DelveInsight<\/a><\/strong><\/em><\/p>\n

Why should you buy this report? <\/strong><\/em><\/p>\n